Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.

Indian Dermatol Online J · 2017 · PMC5297264 · PMID 28217466

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results showed a trend that the secukinumab 300 mg was relatively better than the secukinumab 150 mg in the Indian patients with moderate to severe psoriasis during the entire study duration.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.